Tuberc Respir Dis.  2010 May;68(5):290-293.

Prostatic Cancer Presenting as an Isolated Large Lung Mass

• No HS
• Lee JH
• Ahn Y
• Na II
• Kim HR
• Kim CH
• Koh JS
• Lee JC

Abstract

A hidden primary tumor presenting as an isolated lung mass is a diagnostic challenge to physicians because the diagnosis of lung cancer is likely to be made if the histologic findings are not inconsistent with lung cancer. A large lung mass was found incidentally in a 59-year-old man. Although adenocarcinoma was diagnosed by percutaneous needle biopsy, thyroid transcription factor-1 (TTF-1) immunostaining was negative, raising suspicion that there was another primary site. There was no abnormal finding except for the lung mass on a 18FDG-PET/CT scan and the patient did not complain of any discomfort. Finally, prostatic cancer was confirmed through the study of tumor markers and prostate-specific antigen (PSA) immunostaining. Because of the rare presentation of a single lung mass in malignancies that have another primary site, physicians should carefully review all data before making a final diagnosis of lung cancer.

Keyword

Metastasis; Prostatic Neoplasms; Thyroid Transcription Factor 1; Tumor Markers, Biological

MeSH Terms

Adenocarcinoma
Biopsy, Needle
Humans
Lung
Lung Neoplasms
Middle Aged
Neoplasm Metastasis
Nuclear Proteins
Prostate-Specific Antigen
Prostatic Neoplasms
Thyroid Gland
Transcription Factors
Biomarkers, Tumor
Nuclear Proteins
Prostate-Specific Antigen
Transcription Factors

Reference

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007. 57:43–66.

2. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer. 2005. 41:834–845.

3. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000. 31:578–583.

4. Fabozzi SJ, Schellhammer PF, el-Mahdi AM. Pulmonary metastases from prostate cancer. Cancer. 1995. 75:2706–2709.

5. Zelefsky MJ, Eastham JA, Sartor OA, Kantoff P. Devita VT, Lawrence TS, Rosenberg S, editors. Chapter 40. Cancers of the genitourinary system. Cancer: principles and practice of oncology. 2008. 8th ed. Philadelphia: Lippincott Williams & Wilkins;1392–1462.

6. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995. 75:191–202.

7. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005. 117:294–299.

8. Yamada T, Ono S, Tsuboi M, Saito H, Sato A, Matsuhashi T, et al. Low-dose CT of the thorax in cancer follow-up. Eur J Radiol. 2004. 51:169–174.

9. Weng MJ, Wu MT, Pan HB, Kan YY, Yang CF. The feasibility of low-dose CT for pulmonary metastasis in patients with primary gynecologic malignancy. Clin Imaging. 2004. 28:408–414.

10. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology. 2006. 48:223–232.

11. Choi YH, Park KY, Ryoo BY, Na II, Yang SH, Koh JS, et al. Presence of malignant mesothelial cells in the sputum. Intern Med. 2008. 47:57–60.

12. Moldvay J, Jackel M, Bogos K, Soltész I, Agócs L, Kovács G, et al. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res. 2004. 10:85–88.

13. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002. 55:662–668.